All of the patients included in the initial study sample were taken into account when estimating the effectiveness. The health outcomes used in the analysis were:
the mean number of days of neutropenia after starting G-CSF,
the mean number of days with leukocytosis after starting G-CSF,
the mean number of days to G-CSF therapy after hospitalisation, and
the average length of hospital stay after starting G-CSF.
The two study groups were shown to be comparable at baseline for demographic and clinical conditions, although those in the IP group had a lower CD4 count.